An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
Jiang Y, Zhou X, Wong H, Ouyang L, Ip F, Chau V, Lau S, Wu W, Wong D, Seo H, Fu W, Lai N, Chen Y, Chen Y, Tong E, Mok V, Kwok T, Mok K, Shoai M, Lehallier B, Losada P, O’Brien E, Porter T, Laws S, Hardy J, Wyss-Coray T, Masters C, Fu A, Ip N. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease. Nature Aging 2022, 2: 616-634. PMID: 37117777, PMCID: PMC10154240, DOI: 10.1038/s43587-022-00241-9.Peer-Reviewed Original ResearchConceptsAssociated with Alzheimer's diseaseGenetic variantsGenome-wide association analysisDisease-causing roleCRISPR-Cas9 genome editingEuropean-descent populationsAlzheimer's diseaseMouse transcriptomeDisease-causing factorsGenetic variationAmyloid-betaEnhancer elementsAssociation analysisDownregulated genesAD riskGenome editingMendelian randomization analysisLower AD riskDecoy receptorProtein levelsAPOE-e4Female individualsProteinVariantsModulation of microglial activation